CFL1 and lymphangioleiomyomatosis: A specific inhibitor of mTOR, sirolimus, was employed to further investigate cofilin, and the Western blotting results revealed lower p-cofilin levels in the lung tissues of LAM patients treated with sirolimus than in LAM patients not treated with the inhibitor, and ROCK1, LIMK, and SSh1 expression did not change significantly (Figure 4a).